Skip to main content
NVCT logo

NVCT

Nuvectis Pharma, Inc.

$19.38

2.31%

Trade Ideas Performance

Latest Closed Trade Idea

$19.38

2.31%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

9

Social

32

About

Events of Nuvectis Pharma, Inc. (NVCT)

In the past six months, Nuvectis Pharma reported its Third Quarter 2026 financial results on November 4, 2026, showing a wider-than-expected EPS loss but a stronger cash position extending funding into the second half of 2029. On October 26, 2026, the company announced positive, expanded data from its NXP200 Phase 1b study, demonstrating durable responses in gliomas. NXP200 was granted Breakthrough Therapy Designation in China for high-grade glioma on September 24, 2026. Nuvectis Pharma's partner, Haisco, received marketing approval from China's NMPA for Ciprocopan (NXP100) on July 23, 2026. In July 2026, the company completed an equity offering that raised approximately $115 million. The stock experienced a surge of approximately 97% over a three-month period in August 2026, reflecting optimism around its expanding pipeline. Nuvectis Pharma also participated in several investor conferences during this period, including the Maxim Growth Summit and the H.C. Wainwright Annual Global Investment Conference.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)